Late angiotensin II receptor blockade in progressive rat mesangioproliferative glomerulonephritis: New insights into mechanisms

Journal of Pathology

Volumn 229, Issue 5, 2013, Pages 672-684

  Villa, Luigi ^a   Boor, Peter ^a   Konieczny, Andrzej ^a,b   Kunter, Uta ^a   Van Roeyen, Claudia R C ^a   Denecke, Bernd ^a   Gan, Lin ^a   Neusser, Matthias A ^c   Cohen, Clemens D ^c   Eitner, Frank ^a   Scholl, Thomas ^a   Ostendorf, Tammo ^a   Floege, Jürgen ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b Provincial Specialized Hospital   (Poland)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

chemokine; chemokine receptor; fibrosis; IgA nephropathy; mesangioproliferative glomerulonephritis; platelet derived growth factor receptor; renin angiotensin system; telmisartan

Indexed keywords

ANGIOTENSIN RECEPTOR; ATENOLOL; CHEMOKINE RECEPTOR CCR6; HYDRALAZINE; HYDROCHLOROTHIAZIDE; MESSENGER RNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; TELMISARTAN; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VIMENTIN;

ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CELL INFILTRATION; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DOWN REGULATION; DRUG EFFECT; DRUG MEGADOSE; GLOMERULOSCLEROSIS; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOGLOBULIN A NEPHROPATHY; IN VITRO STUDY; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LOW DRUG DOSE; MACROPHAGE; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; NONHUMAN; OUTCOME ASSESSMENT; PODOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; RECEPTOR BLOCKING; RENAL PROTECTION; TREATMENT DURATION; UPREGULATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ANTIHYPERTENSIVE AGENTS; ATENOLOL; BENZIMIDAZOLES; BENZOATES; BLOOD PRESSURE; CELL DEDIFFERENTIATION; CELL LINE; CHEMOKINE CCL20; CYTOPROTECTION; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLOMERULAR MESANGIUM; GLOMERULONEPHRITIS, MEMBRANOPROLIFERATIVE; HUMANS; HYDRALAZINE; HYDROCHLOROTHIAZIDE; HYPERTENSION; INFLAMMATION; ISOANTIBODIES; MACROPHAGES; MALE; MICE; NEPHRECTOMY; PODOCYTES; PROTEINURIA; RATS; RATS, WISTAR; RECEPTORS, CCR6; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RNA INTERFERENCE; RNA, MESSENGER; TIME FACTORS; TRANSFECTION;

EID: 84875054368     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4151     Document Type: Article

References (30)

1. Barratt J, Feehally J,. Treatment of IgA nephropathy. Kidney Int 2006; 69: 1934-1938.
2. Locatelli F, Vecchio LD, Pozzi C,. IgA glomerulonephritis: beyond angiotensin-converting enzyme inhibitors. Nat Clin Pract Nephrol 2006; 2: 24-31.
3. Villa L, Boor P, Konieczny A, et al,. Effects and mechanisms of angiotensin II receptor blockade in a normotensive model of mesangioproliferative glomerulonephritis. Nephrol Dial Transpl 2011; 26 (10): 3131-3143.
4. Krämer S, Kron S, Wang-Rosenke Y, et al,. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesiangioproliferative glomerulosclerosis. Am J Physiol Renal Physiol 2008; 294 (4): F801-811.
5. Kondo S, Shimizu M, Urushihara M, et al., Addition of the antioxidant probucol to angiotensin II type I receptor antagonist arrest progressive mesangioproliferative glomerulonephritis in the rat. J Am Soc Nephrol 2006; 17: 783-794.
6. Tanaka T, Matsumoto M, Inagi R, et al., Induction of protective genes by cobalt ameliorates tubulointerstitial injury in the progressive Thy1 nephritis. Kidney Int 2005; 68: 2714-2725.
7. Nakamura T, Obata J, Kimura H, et al., Blocking angiotensin II ameliorates proteinuria and glomerular lesions in progressive mesangioproliferative glomerulonephritis. Kidney Int 1999; 55: 877-889.
8. Tomita M, Sogabe H, Nakazato S, et al., Monoclonal antibody 1-22-3-induced glomerulonephritis in uninephrectomized rats as a model of progressive renal failure. Nephrol Dial Transpl 2005; 20: 2358-2367.
9. Shinosaki T, Miyai I, Nomura Y, et al., Mechanisms underlying the ameliorative property of lisinopril in progressive mesangioproliferative nephritis. Nephron 2002; 91: 719-729.
10. Krämer S, Loof T, Martini S, et al., Mycophenolate mofetil slows progression in anti-thy1-induced chronic renal fibrosis but is not additive to a high dose of enalapril. Am J Physiol Renal Physiol 2005; 289: 359-368.
11. Asai M, Monkawa T, Marumo T, et al., Spironolactone in combination with cilazapril ameliorates proteinuria and renal interstitial fibrosis in rats with anti-Thy1 irreversible nephritis. Hypertens Res 2004; 27: 971-978.
12. Floege J, Eitner F, Alpers CE,. A new look at platelet-derived growth factor in renal disease. J Am Soc Nephrol 2008; 19: 12-23.
13. Ostendorf T, Rong S, Boor P, et al,. Antagonism of PDGF-D by human antibody CR002 prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2006; 17: 1054-1062.
14. Ostendorf T, van Roeyen CR, Peterson JD, et al., A fully human monoclonal antibody (CR002) identifies PDGF-D as a novel mediator of mesangioproliferative glomerulonephritis. J Am Soc Nephrol 2003; 14: 2237-2247.
15. Ostendorf T, Kunter U, Grone HJ, et al., Specific antagonism of PDGF prevents renal scarring in experimental glomerulonephritis. J Am Soc Nephrol 2001; 12: 909-918.
16. Ibrahim J, Berk BC, Hughes AD, et al,. Comparison of simultaneous measurements of blood pressure by tail-cuff and carotid arterial methods in conscious spontaneously hypertensive and Wistar-Kyoto rats. Clin Exp Hypertens 2006; 28 (1): 57-72.
17. Schiwek D, Endlich L, Holzmann, et al. Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. Kidney Int 2004; 66: 91-101.
18. Liu Y., Epithelial-to-mesenchymal transition in renal fibrogenesis: pathologic significance, molecular mechanism, and therapeutic intervention. J Am Soc Nephrol 2004; 15: 1-12.
19. Rastaldi MP, Ferrario F, Giardino L, et al., Epithelial-mesenchymal transition of tubular epithelial cells in human renal biopsies. Kidney Int 2002; 62: 137-146.
20. van Roeyen CR, Eitner F, Boor P, et al,. Induction of progressive glomerulonephritis by podocyte-specific overexpression of platelet-derived growth factor-D. Kidney Int 2011; 80 (12): 1292-1305.
21. Marshall TG, Lee R, Marshall FE,. Common angiotensin receptor blockers may directly modulate the immune system via VDR, PPAR and CCR2b. Theor Biol Med Model 2006; 3 (1): 1-33.
22. Benson SC, Pershadsingh HA, Ho CI, et al,. Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARγ-modulating activity. Hypertension 2004; 43: 993-1002.
23. Hsu HH, Hoffmann S, Endlich N, et al,. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med (Berl) 2008; 86 (12): 1379-1394.
24. Wong J, Rauhoft C, Dilley RJ, et al,. Angiotensin-converting enzyme inhibition abolishes medial smooth muscle PDGF-AB biosynthesis and attenuates cell proliferation in injured carotid arteries: relationships to neointima formation. Circulation 1997; 96: 1631-1640.
25. Kliem V, Johnson RJ, Alpers CE, et al,. Mechanisms involved in the pathogenesis of tubulointerstitial fibrosis in 5/6-nephrectomized rats. Kidney Int 1996; 49 (3): 666-678.
26. Taneda S, Hudkins KL, Topouzis S, et al,. Obstructive uropathy in mice and humans: potential role for PDGF-D in the progression of tubulointerstitial injury. J Am Soc Nephrol 2003; 14 (10): 2544-2555.
27. Eitner F, Bücher E, van Roeyen C, et al,. PDGF-C is a proinflammatory cytokine that mediates renal interstitial fibrosis. J Am Soc Nephrol 2008; 19 (2): 281-289.
28. Schutyser E, Struyf S, Van Damme J,. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev 2003; 14 (5): 409-426.
29. Woltman AM, de Fijter JW, van der Kooij SW, et al,. MIP-3α/CCL20 in renal transplantation and its possibile involvement as dendritic cell chemoattractant in allograft rejection. Am J Transpl 2005; 5: 2114-2125.
30. Welsh-Bacic D, Lindenmeyer M, Cohen CD, et al,. Expression of the chemokine receptor CCR6 in human renal inflammation. Nephrol Dial Transpl 2011; 26 (4): 1211-1220.